Line 72: | Line 72: | ||
<ul> | <ul> | ||
− | <li>iGEM 2008-2011 | + | <li>iGEM 2008-2011</li> |
− | <li>Led the 2011 Grand Prize Winner, Washington | + | <li>Led the 2011 Grand Prize Winner, Washington </li> |
− | <li>Founded PVP Bio with the team project from 2011 | + | <li>Founded PVP Bio with the team project from 2011</li> |
− | <li>PVP Bio got $35 million investment from Takeda Pharmaceuticals | + | <li>PVP Bio got $35 million investment from Takeda Pharmaceuticals</li> |
</ul> | </ul> | ||
</div> | </div> | ||
Line 104: | Line 104: | ||
<ul> | <ul> | ||
− | <li>Part of the first year of iGEM in 2004 | + | <li>Part of the first year of iGEM in 2004</li> |
− | <li> One of the leaders of the iGEM 2006 MIT team with Eau d’coli | + | <li> One of the leaders of the iGEM 2006 MIT team with Eau d’coli</li> |
− | <li> Founded Ginkgo Bioworks with 4 other iGEMers | + | <li> Founded Ginkgo Bioworks with 4 other iGEMers</li> |
</ul> | </ul> | ||
</div> | </div> | ||
+ | |||
+ | |||
+ | |||
+ | <div class="clear extra_space"></div> | ||
+ | |||
+ | <div class="column quarter_size"> | ||
+ | <img src="https://cdn.the-scientist.com/assets/articleNo/32764/iImg/6640/2c16e032-f404-4b83-a45e-92cc5ae218b3-profile.jpg"> | ||
+ | </div> | ||
+ | |||
+ | <div class="column half_size"> | ||
+ | <h3>George Church </h3> | ||
+ | <h4> <a href="https://wyss.harvard.edu/team/core-faculty/george-church/">Wyss Institute </a> </h4> | ||
+ | <p> | ||
+ | George Church is Professor of Genetics at Harvard Medical School and Director of PersonalGenomes.org, which provides the world's only open-access information on human Genomic, Environmental & Trait data (GET). His 1984 Harvard PhD included the first methods for direct genome sequencing, molecular multiplexing & barcoding. These led to the first genome sequence (pathogen, Helicobacter pylori) in 1994 . His innovations have contributed to nearly all "next generation" DNA sequencing methods and companies (CGI-BGI, Life, Illumina, Nanopore). This plus his lab's work on chip-DNA-synthesis, gene editing and stem cell engineering resulted in founding additional application-based companies spanning fields of medical diagnostics ( Knome/PierianDx, Alacris, AbVitro/Juno, Genos, Veritas Genetics ) & synthetic biology / therapeutics ( Joule, Gen9, Editas, Egenesis, enEvolv, WarpDrive ). He has also pioneered new privacy, biosafety, ELSI, environmental & biosecurity policies. He is director of an IARPA BRAIN Project and NIH Center for Excellence in Genomic Science. His honors include election to NAS & NAE & Franklin Bower Laureate for Achievement in Science. He has coauthored 480 papers, 130 patent publications & one book (Regenesis). | ||
+ | </p> | ||
+ | </div> | ||
+ | |||
+ | <div class="column quarter_size"> | ||
+ | |||
+ | <h4> iGEM Experience </h4> | ||
+ | |||
+ | <ul> | ||
+ | <li>Participated in the first year of iGEM in 2004 </li> | ||
+ | <li>Led iGEM teams for many years </li> | ||
+ | </ul> | ||
+ | |||
+ | </div> | ||
Revision as of 18:38, 16 August 2018
SUNDAY SCHEDULE
Lorem ipsum
More events and activities will be added, stay tuned!
Keynote Speakers
Lorem ipsum
![](https://www.pvpbio.com/wp-content/uploads/2017/03/Ingrid-1.jpg)
Ingrid Swanson Pultz
CSO of PVP Biologics
Ingrid Swanson Pultz, Ph.D., is a co-founder and the chief scientific officer of PvP Biologics. Dr. Pultz is a leader in computational enzyme design, and has a distinguished track record of leading research teams to success. As an inventor of PvP’s gluten-degrading enzyme technology and an entrepreneur, Dr. Pultz has established cross-disciplinary connections and bridged industry with academia to accomplish research goals. Dr. Pultz established PvP Biologics in 2012 and joined the team as its chief scientific officer in 2016. Prior to PvP Biologics, Dr. Pultz led the effort to develop effective therapeutics for celiac disease at the Institute for Protein Design at the University of Washington, where she held a faculty position in the Department of Biochemistry. Dr. Pultz completed her Ph.D. in microbiology at Washington in the laboratory of Dr. Samuel Miller, and post-doctoral research with Dr. David Baker. She holds a B.A. in biology from Wellesley College. While operating at the forefront of protein engineering, Dr. Pultz also has a strong interest in training the next generation of effective leaders in science and technology. Dr. Pultz has received numerous awards and recognitions including a Life Sciences Discovery Fund grant, the Neil Groman Award for Excellence in Teaching, and a competitive NSF research fellowship.
iGEM Experience
- iGEM 2008-2011
- Led the 2011 Grand Prize Winner, Washington
- Founded PVP Bio with the team project from 2011
- PVP Bio got $35 million investment from Takeda Pharmaceuticals
![](http://1nbdvg2h9y331q33ay3md3ni.wpengine.netdna-cdn.com/wp-content/uploads/2017/06/Jason_Kelly-600x600-c-default.jpg)
Jason Kelly
CEO of Ginkgo Bioworks
Jason Kelly co-founded Ginkgo BioWorks in 2008. The organism is the product at Ginkgo BioWorks. Ginkgo's organism engineers design microbes made-to-order for customers across a range of industries by leveraging a technology platform including custom hardware, software, and wetware. Jason earned his PhD from MIT in Biological Engineering in 2008, under professor Drew Endy, and his BS in Chemical Engineering and Biology in 2003. His doctoral research included the development of a widely adopted measurement standard for characterizing transcriptional elements.
iGEM Experience
- Part of the first year of iGEM in 2004
- One of the leaders of the iGEM 2006 MIT team with Eau d’coli
- Founded Ginkgo Bioworks with 4 other iGEMers
![](https://cdn.the-scientist.com/assets/articleNo/32764/iImg/6640/2c16e032-f404-4b83-a45e-92cc5ae218b3-profile.jpg)
George Church
Wyss Institute
George Church is Professor of Genetics at Harvard Medical School and Director of PersonalGenomes.org, which provides the world's only open-access information on human Genomic, Environmental & Trait data (GET). His 1984 Harvard PhD included the first methods for direct genome sequencing, molecular multiplexing & barcoding. These led to the first genome sequence (pathogen, Helicobacter pylori) in 1994 . His innovations have contributed to nearly all "next generation" DNA sequencing methods and companies (CGI-BGI, Life, Illumina, Nanopore). This plus his lab's work on chip-DNA-synthesis, gene editing and stem cell engineering resulted in founding additional application-based companies spanning fields of medical diagnostics ( Knome/PierianDx, Alacris, AbVitro/Juno, Genos, Veritas Genetics ) & synthetic biology / therapeutics ( Joule, Gen9, Editas, Egenesis, enEvolv, WarpDrive ). He has also pioneered new privacy, biosafety, ELSI, environmental & biosecurity policies. He is director of an IARPA BRAIN Project and NIH Center for Excellence in Genomic Science. His honors include election to NAS & NAE & Franklin Bower Laureate for Achievement in Science. He has coauthored 480 papers, 130 patent publications & one book (Regenesis).
iGEM Experience
- Participated in the first year of iGEM in 2004
- Led iGEM teams for many years